•
MB
MBRX
Moleculin Biotech, Inc.
yahooPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
14.66M
Volume
215.71K
52W High
$91.25
52W Low
$3.13
Open
$0.00
Prev Close
$4.26
Day Range
0.00 - 0.00
About Moleculin Biotech, Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
Latest News
Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain | DelveInsight
GlobeNewswire Inc.•Dec 4
Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)
GlobeNewswire Inc.•Jun 4
Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference
Benzinga•Mar 11
Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium
Benzinga•Mar 3
Moleculin Participates in Virtual Investor "What This Means" Segment
Benzinga•Jan 27
Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026
Benzinga•Jan 8
Bitget Wallet Expands DeSci Ecosystem Access
GlobeNewswire Inc.•Dec 26
Moleculin Participates in Virtual Investor "What this Means" Segment
Benzinga•Sep 16